D-Pantethine

Research use only, not for human use.

Pantethine is a dimeric form of pantothenic acid, is an intermediate in the production of Coenzyme A.

Pantethine is a dimeric form of pantothenic acid, is an intermediate in the production of Coenzyme A, is available as a dietary supplement, and is used to treat acne and improve the blood-cholesterol profile.

Western Blot Analysis Cell Line:Calu-3a, Vero E6Concentration:50 μM, 100 μM, 250 μM, 500 μM, 1000 μMIncubation Time:Cell were pretreated with Pantethine for 1 h prior to virus infection, followed by incubation with the virus for 2 h in the presence of Pantethine until the end of the experiment.Result:Decreased the expression of viral spike (S) and nucleocapsid (N) proteins.RT-PCR Cell Line:Calu-3a, Vero E6Concentration:50 μM, 100 μM, 250 μM, 500 μM, 1000 μMIncubation Time: Cell were pretreated with Pantethine for 1 h prior to virus infection, followed by incubation with the virus for 2 h in the presence of Pantethine until the end of the experiment.Result:Significantly reduced the copy number of viral nucleapsid (N) and non-structural protein 6 (NSP6) genes in the cell supernatant.Decreased the mRNA expression levels of HECT E3 ligase and TMPRSS2 in virus-induced infected cells.Significantly decreased the mRNA expression of MAVS, IRF3, IFNβ, STING, TNF-α and IL6 in Calu-3a cells, and decreased the inflammation caused by SARS-CoV-2 virus infection.

Animal Model:Male Sprague–Dawley rats modelDosage:1.2 mmol/kg Administration:Intragastrical administration (i.g.); Single doseResult:Reduced plasma free fatty acid (FFA), cholesterol, and triglyceride levels at 3, 5, 7, and 24 h, while significantly increased glycerol levels at 7 h.Animal Model:Orthotopic female rats model of ovarian cancer Dosage:750 mg/kg Administration:Intraperitoneal injection (i.p.); Once daily for 4 weeks Result:Reduced tumor growth, metastasis and ascites, and had no toxicity to liver and kidney.Animal Model:Systemic sclerosis (SSc) BALB/c mice model Dosage:15 mg/kg Administration:Oral gavage (p.o.); Once daily for 6 weeks. After HOCL treatment ( 200 μM; Intradermal injection; Once daiy for 6 weeks).Result:Decreased the number of MPs in mice endothelial cells.Decreased the concentrations of soluble E-selectin and sVCAM-1 in serum.Decreased serum concentration of AOPPs (33%) and nitrate (60%).Animal Model:Ketogenic diet mouse model Dosage:150 mg/kg Administration:Supplemented in daily drinking water, for 2 months. Follow a casual ketogenic diet during this period.Result:Alleviated motor dysfunction, neurodegeneration and changes in mitochondria of the central and peripheral nervous systems in mice.

Pantethine | LBF disulfide | Lipodel | Pantosin | D-Pantethine

Metabolic Enzyme/Protease

Vitamin

VB5

Other Indications

——

16816-67-4

554.72

C22H42N4O8S2

>98% (HPLC)

DMSO: ≥ 30 mg/mL; Water: ≥ 80 mg/mL

O=C(NCCSSCCNC(CCNC([C@H](O)C(C)(C)CO)=O)=O)CCNC([C@H](O)C(C)(C)CO)=O

(2R,2'R)-N,N'-(((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))bis(3-oxopropane-3,1-diyl))bis(2,4-dihydroxy-3,3-dimethylbutanamide)

(-20℃)

With Ice Pack

≥ 2 years